Long-Acting Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Children: Results of a Phase 3 Trial

A global phase 3 study evaluated the pharmacokinetics, efficacy and safety of a recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in 27 previously treated male children (1–11 years) with severe and moderately severe haemophilia B (factor IX [FIX] activity ≤2 IU/dl). All...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Thromb Haemost
Glavni autori: Kenet, Gili, Chambost, Hervé, Male, Christoph, Lambert, Thierry, Halimeh, Susan, Chernova, Tatiana, Mancuso, Maria Elisa, Curtin, Julie, Voigt, Christine, Li, Yanyan, Jacobs, Iris, Santagostino, Elena
Format: Artigo
Jezik:Inglês
Izdano: Schattauer 2016
Teme:
Coagulation and Fibrinolysis
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5039316/
https://ncbi.nlm.nih.gov/pubmed/27583313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1160/TH16-03-0179
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items